title: Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.
authors.affiliation: Division of Hematology, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: A
authors.initials: A
authors.lastname: Zhou
authors.affiliation: Division of Hematology, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: E M
authors.initials: EM
authors.lastname: Knoche
authors.affiliation: Division of Hematology, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: E K
authors.initials: EK
authors.lastname: Engle
authors.affiliation: Division of Hematology, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: D A C
authors.initials: DA
authors.lastname: Fisher
authors.affiliation: Division of Hematology, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: S T
authors.initials: ST
authors.lastname: Oh
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069439:Dasatinib / Q000008:administration & dosage; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D009570:Nitriles; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D011720:Pyrazoles / Q000008:administration & dosage; D011743:Pyrimidines
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D016044:Fusion Proteins, bcr-abl; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D000069439:Dasatinib